Journal List > Perinatology > v.30(1) > 1127209

Kim, Jang, Moon, Shin, Lee, Choi, Hong, and Oh: The Relationship between Histological Chorioamnionitis and Bronchopulmonary Dysplasia in Low-Birth Weight Infants: Changes of C-Reactive Protein in Bron chopulmonary Dysplasia

Abstract

Objective

Intrauterine inflammation caused by chorioamnionitis has been related with various perinatal morbidities which increase the risk of bronchopulmonary dysplasia (BPD). C-reactive protein (CRP) is a well known biomarker of inflammation. We aimed to investigate the relationship between histological chorioamnionitis (HCA) and BPD, and also to observe the changes of CRP in BPD.

Methods

Low-birth-weight infants (LBWIs) admitted to the neonatal intensive care unit between January 2011 and October 2017 were reviewed. Perinatal morbidities associated with BPD including maternal HCA were observed. Also, changes of CRP were analyzed.

Results

A total of 584 LBWIs were analyzed and 168 (28.8%) had HCA and 46 (7.9%) had BPD. The development of BPD was associated with gestational age, birth weight, 1 and 5 minutes Apgar scores, the presence of preterm premature rupture of membrane, prenatal antibiotics, respiratory distress syndrome (RDS), ventilator application, early onset sepsis, necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, patent ductus arteriosus and HCA. The multiple logistic regression model for BPD showed that the risk factors of BPD were lower gestational age, lower birth weight, patent ductus arteriosus (PDA). Chorioamnionitis was not a significant risk factor for BPD (aOR, 1.477; 95% CI, 0.376–5.806). Infants with BPD were likely to have higher CRP on day 0 and day 7.

Conclusion

Our study suggests that the primary risk factors of BPD in LBWIs are lower gestational age, lower birth weight, RDS, ventilator application and PDA rather than HCA. In infants with BPD, CRP was significantly higher on day 0 and day 7.

References

1. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006; 11:354–62.
crossref
2. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015; 213(4 Suppl):S29–52.
crossref
3. Malavolti AM, Bassler D, Arlettaz-Mieth R, Faldella G, Latal B, Natalucci G. Bronchopulmonary dysplasia-impact of severity and timing of diagnosis on neurodevelopment of preterm infants: a retrospective cohort study. BMJ Paediatr Open. 2018; 2:e000165.
crossref
4. You JY, Shu C, Gong CH, Liu S, Fu Z. Readmission of children with bronchopulmonary dysplasia in the first 2 years of life: a clinical analysis of 121 cases. Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19:1056–60.
5. Bozzetto S, Carraro S, Tomasi L, Berardi M, Zanconato S, Baraldi E. Health-related quality of life in adolescent survivors of bronchopulmonary dysplasia. Respirology. 2016; 21:1113–7.
crossref
6. Redline RW. Classification of placental lesions. Am J Obstet Gynecol. 2015; 213(4 Suppl):S21–8.
crossref
7. Gravett MG, Hitti J, Hess DL, Eschenbach DA. Intrauterine infection and preterm delivery: evidence for activation of the fetal hypothalamic-pituitary-adrenal axis. Am J Obstet Gynecol. 2000; 182:1404–13.
crossref
8. Balany J, Bhandari V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. Front Med (Lausanne). 2015; 2:90.
crossref
9. Eriksson L, Haglund B, Odlind V, Altman M, Ewald U, Kieler H. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. Acta Paediatr. 2015; 104:259–63.
crossref
10. Stranak Z, Feyereisl J, Korcek P, Feyereislova S, Krofta L. Procalcitonin is more likely to be released by the fetus rather than placental tissue during chorioamnionitis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016; 160:499–502.
crossref
11. Torchin H, Lorthe E, Goffinet F, Kayem G, Subtil D, Truffert P, et al. Histologic chorioamnionitis and bronchopulmonary dysplasia in preterm infants: the epidemiologic study on low gestational ages 2 cohort. J Pediatr. 2017; 187:98–104.e3.
crossref
12. Matsumura H, Ichiba H, Ohnishi S, Saito M, Shintaku H. Histologic chorioamnionitis, amniotic fluid interleukin 6, krebs von den lungen 6, and transforming growth factor β1 for the development of neonatal bronchopulmonary dysplasia. Jpn Clin Med. 2017; 8:1179066017696076.
crossref
13. Kaneko M, Sato M, Ogasawara K, Imamura T, Hashimoto K, Momoi N, et al. Serum cytokine concentrations, chorioamnionitis and the onset of bronchopulmonary dysplasia in premature infants. J Neonatal Perinatal Med. 2017; 10:147–55.
crossref
14. Samejima T, Takechi K. Elevated C-reactive protein levels in histological chorioamnionitis at term: impact of funisitis on term neonates. J Matern Fetal Neonatal Med. 2017; 30:1428–33.
crossref
15. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163:1723–9.
crossref
16. Salafia CM, Weigl C, Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol. 1989; 73:383–9.
crossref
17. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010; 126:443–56.
crossref
18. Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr. 1991; 119:285–92.
19. Yu KH, Li J, Snyder M, Shaw GM, O'Brodovich HM. The genetic predisposition to bronchopulmonary dysplasia. Curr Opin Pediatr. 2016; 28:318–23.
crossref
20. Ali Z, Schmidt P, Dodd J, Jeppesen DL. Bronchopulmonary dysplasia: a review. Arch Gynecol Obstet. 2013; 288:325–33.
crossref
21. Glaser K, Speer CP. Pre and Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia, in Bronchopulmonary Dysplasia, edited by Bhandari V, Cham. Springer International Publishing;2016. p.p. 55–77.
22. Viscardi RM. Perinatal inflammation and lung injury. Semin Fetal Neonatal Med. 2012; 17:30–5.
crossref
23. Speer CP. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 2009; 95:353–61.
crossref
24. Palmsten K, Nelson KK, Laurent LC, Park S, Chambers CD, Parast MM. Subclinical and clinical chorioamnionitis, fetal vasculitis, and risk for preterm birth: a cohort study. Placenta. 2018; 67:54–60.
crossref
25. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996; 97:210–5.
crossref
26. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol. 1997; 177:825–30.
27. Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and metaanalysis. Arch Dis Child Fetal Neonatal Ed. 2012; 97:F8–17.
crossref
28. Kramer BW, Kallapur S, Newnham J, Jobe AH. Prenatal inflammation and lung development. Semin Fetal Neonatal Med. 2009; 14:2–7.
crossref
29. Kramer BW, Ladenburger A, Kunzmann S, Speer CP, Been JV, van Iwa-arden JF, et al. Intravenous lipopolysaccharide-induced pulmonary maturation and structural changes in fetal sheep. Am J Obstet Gynecol. 2009; 200:195e1–10.
crossref
30. Thomas W, Speer CP. Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome? Neonatology. 2011; 99:177–87.
crossref
31. Choi CW, Lee J, Oh JY, Lee SH, Lee HJ, Kim BI. Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats. Pediatr Res. 2016; 79:287–94.
crossref
32. Paananen R, Husa AK, Vuolteenaho R, Herva R, Kaukola T, Hallman M. Blood cytokines during the perinatal period in very preterm infants: relationship of inflammatory response and bronchopulmonary dysplasia. J Pediatr. 2009; 154:39–43.e3.
crossref
33. Plakkal N, Soraisham AS, Trevenen C, Freiheit EA, Sauve R. Histological chorioamnionitis and bronchopulmonary dysplasia: a retrospective cohort study. J Perinatol. 2013; 33:441–5.
crossref
34. Ballard AR, Mallett LH, Pruszynski JE, Cantey JB. Chorioamnionitis and subsequent bronchopulmonary dysplasia in very-low-birth weight infants: a 25-year cohort. J Perinatol. 2016; 36:1045–8.
crossref
35. Stimac M, Juretić E, Vukelić V, Matasić NP, Kos M, Babić D. Effect of chorioamnionitis on mortality, early onset neonatal sepsis and bronchopulmonary dysplasia in preterm neonates with birth weight of <1,500 grams. Coll Antropol. 2014; 38:167–71.
36. Choi CW. Chorioamnionitis: is a major player in the development of bronchopulmonary dysplasia? Korean J Pediatr. 2017; 60:203–7.
crossref
37. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013; 56:131–42.
crossref
38. Lee J, Bang YH, Lee EH, Choi BM, Hong YS. The influencing factors on procalcitonin values in newborns with noninfectious conditions during the first week of life. Korean J Pediatr. 2017; 60:10–6.
crossref
39. Chiesa C, Signore F, Assumma M, Buffone E, Tramontozzi P, Osborn JF, et al. Serial measurements of C-reactive protein and interleukin-6 in the immediate postnatal period: reference intervals and analysis of maternal and perinatal confounders. Clin Chem. 2001; 47:1016–22.
crossref
40. Chiesa C, Natale F, Pascone R, Osborn JF, Pacifico L, Bonci E, et al. C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. Clin Chim Acta. 2011; 412:1053–9.
crossref

Table 1.
Demographic and Clinical Findings in Low-birth-weight In fants with and without Histological Chorioamnionitis
  HCA No HCA P-value
N 168 (28.8) 416 (71.2)  
Gestational age (weeks) 32.7±3.7 34.4±2.94 <0.001
<28 21 (12.5) 13 (3.1) <0.001
28–31 33 (19.6) 52 (12.5) 0.027
≥32 114 (67.9) 351 (84.4) 0.016
Birth weight (g) 1,767±499 1,953±464 <0.001
Male sex 81 (48.2) 199 (47.8) 0.934
Cesarean section 94 (56.0) 303 (72.8) <0.001
Apgar, 1 minute 6.3±2.47 6.7±2.01 0.059
Apgar, 5 minutes 8.3±1.71 8.6±1.45 0.069
PROM (>18 hours) 56 (33.3) 72 (17.3) <0.001
GDM 26 (15.7) 75 (18.0) 0.460
Early onset sepsis 3 (1.8) 4 (1.0) 0.415
Ventilator application 67 (39.9) 106 (25.5) 0.001
RDS 50 (29.8) 54 (13.0) <0.001
IVH 36 (21.4) 51 (12.3) 0.005
BPD 25 (14.9) 21 (5.0) <0.001
Mild 11 (6.5) 3 (0.7) <0.001
Moderate to severe 14 (8.3) 18 (4.3) 0.054
Gestational age (weeks)      
<28 19 (76.0) 12 (57.2) 0.174
28–31 6 (24.0) 7 (33.3) 0.484
≥32 0 (0.0) 2 (9.5) 0.203
PDA 51 (30.4) 93 (22.4) 0.042

Values are presented as mean±standard deviation or number (%). Abbreviations: HCA, histological chorioamnionitis; PROM, premature rupture o membrane; GDM, gestational diabetes mellitus; RDS, respiratory distress synd rome; IVH, intraventricular hemorrhage; BPD, bronchopulmonary dysplasia; PDA patent ductus arteriosus.

Table 2.
Multiple Logistic Regression for Bronchopulmonary Dysplasia
Variable OR (95% CI) P-value Adjusted OR (95% CI) P-value
Gestational age (weeks) 0.376 (0.291–0.487) <0.001 0.659 (0.439–0.989) 0.044
Birth weight (g) 0.995 (0.993–0.996) <0.001 0.996 (0.993–0.999) 0.004
Apgar, 1 minute 0.507 (0.429–0.599) <0.001 0.666 (0.430–1.031) 0.069
Apgar, 5 minutes 0.410 (0.327–0.514) <0.001 1.239 (0.730–2.102) 0.428
PROM 3.105 (1.637–5.889) 0.001 2.334 (0.469–11.614) 0.300
Prenatal antibiotics 4.110 (2.016–8.379) <0.001 1.915 (0.400–9.175) 0.416
Early onset sepsis 17.398 (3.766–80.370) <0.001 0.142 (0.012–1.629) 0.117
NEC 4.800 (1.985–11.606) <0.001 0.133 (0.020–0.889) 0.037
IVH 3.919 (2.048–7.502) <0.001 2.475 (0.550–11.136) 0.238
ROP 74.525 (32.144–172.784) <0.001 1.133 (0.230–5.577) 0.878
PDA 19.358 (8.773–42.717) <0.001 4.259 (1.082–16.767) 0.038
HCA 3.288 (1.785–6.057) <0.001 1.477 (0.376–5.806) 0.419
Day 7 CRP (mg/dL) 1.057 (1.011–1.105) 0.014 1.081 (1.020–1.145) 0.009

Abbreviations: OR, odds ratio; CI, confidence interval; PROM, premature rupture of membrane; NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage; ROP, retin-

Table 3.
Comparison of C-reactive Protein Levels according to th Presence of Bronchopulmonary Dysplasia
  BPD No BPD P-valu
CRP (mg/dL)      
Day 0 0.15 (0.10–0.32) (n=46) 0.13 (0.10–0.20) (n=522) 0.027
Day 3 1.59 (0.68–4.78) (n=45) 1.12 (0.55–2.75) (n=498) 0.072
Day 7 0.57 (0.34–1.79) (n=39) 0.30 (0.18–0.62) (n=455) <0.001

Values are presented as median (25–75th interquartile). Abbreviations: BPD, bronchopulmonary dysplasia; CRP, C-reactive protein.

TOOLS
Similar articles